FY2021 Earnings Estimate for ProNAi Therapeutics, Inc. (SRRA) Issued By Jefferies Group
ProNAi Therapeutics, Inc. (NASDAQ:SRRA) – Jefferies Group issued their FY2021 earnings per share (EPS) estimates for shares of ProNAi Therapeutics in a research note issued to investors on Monday. Jefferies Group analyst M. Raycroft forecasts that the biotechnology company will post earnings per share of ($0.95) for the year. Jefferies Group currently has a “Buy” rating on the stock.
Other analysts have also issued research reports about the stock. ValuEngine raised shares of ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research raised shares of ProNAi Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $4.00.
ProNAi Therapeutics (NASDAQ:SRRA) traded up 5.7200% on Tuesday, reaching $1.8501. 643,687 shares of the company’s stock traded hands. ProNAi Therapeutics has a 52-week low of $1.10 and a 52-week high of $1.94. The stock’s market cap is $96.70 million. The company’s 50 day moving average is $1.65 and its 200-day moving average is $1.41.
ProNAi Therapeutics (NASDAQ:SRRA) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.01.
An institutional investor recently bought a new position in ProNAi Therapeutics stock. FMR LLC acquired a new position in ProNAi Therapeutics, Inc. (NASDAQ:SRRA) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 197,100 shares of the biotechnology company’s stock, valued at approximately $302,000. FMR LLC owned 0.38% of ProNAi Therapeutics as of its most recent filing with the Securities & Exchange Commission. 55.72% of the stock is currently owned by institutional investors and hedge funds.
ProNAi Therapeutics Company Profile
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.